Treatment with the TROP2 ADC sac-TMT led to a 70% objective response rate and progression-free survival was “significantly ...
Chinese biopharma company Kelun-Biotech announced on Thursday that an antibody drug conjugate it is developing with Merck (MRK), with Keytruda, outperformed the U.S. drugmaker’s anti-PD-1 therapy in a ...
Shares of Merck & Co. (MRK) rose 5% on Friday after the pharmaceutical giant reported positive developments across multiple ...
Summit Therapeutics (SMMT) stock faced a downgrade at H.C. Wainwright after late-stage trial data for Merck’s (MRK) lung cancer drug sac-TMT. Read more here.
May 21 () - Sichuan Kelun-Biotech Biopharmaceutical said on Thursday its experimental treatment combined with partner Merck's ...
The KEYNOTE-671 trial showed a 71% 36-month overall survival rate with perioperative Keytruda, compared to 64% with placebo. FDA approvals for Keytruda, Imfinzi, and Opdivo in perioperative settings ...
Non-Small Cell Lung Cancer KEYTRUDA, in combination with pemetrexed and platinum chemotherapy, is indicated for the first-line treatment of patients with metastatic nonsquamous non-small cell lung ...
China's Kelun Biotech said its antibody-drug conjugate sacituzumab tirumotecan (sac-TMT) in combination with Merck's Keytruda (pembrolizumab) as a first-line treatment for PD-L1-positive advanced ...
Key growth factors for KEYTRUDA include its unparalleled commercial scale, broad approval across multiple tumor types, strong uptake in early-stage therapies, and a robust clinical trial program.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results